

## REMARKS

The above ments are **not** submitted in Response to the Office Action of June 4, 2001. Applicants will respond to this Office Action in the near future.

Newly added claims are submitted for purposes of further preserving applicants' rights with respect to 35 U.S.C. §135(b) in regards to U.S. Patent No. 6,096,764, issued August 1, 2000.

Respectfully submitted,

RECEIVED

AUG 0 2 2001

TECH CENTER 1600/2900

Brion P. Heaney (Reg. No. 32,542)

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza I


2200 Clarendon Boulevard, Suite 1400

Arlington, Virginia 22201 Direct Dial: (703) 812-5308 Facsimile: (703) 243-6410

Internet Address: heaney@mwzb.com

Filed: July 30, 2001

BPH:imm\K:\Sch\1655\Supp Amend 7-01.wpd



## IN THE CLAIMS:

Please add the following new claims 44-50 as follows:

- 44. A method of inhibiting LHRH analog-induced detrimental side effects due to the administration of an LHRH analog to a patient, wherein said detrimental side effect is reduction in bone density, comprising administering to a patient in need thereof an effective amount of anti-estrogen wherein said anti-estrogen is Raloxifen.
  - 45. A method according to claim 44, wherein said patient is a woman.
- 46. A method according to claim 45, wherein said anti-estrogen is administered orally.
- 47. A method according to claim 44, wherein said LHRH analog is Leuprorelin, Buserelin or Zoladex.
  - 48. A pharmaceutical composition comprising Raloxifen and an LHRH analog.
- 49. A pharmaceutical composition according to claim 48, wherein said LHRH analog is Leuprorelin, Buserelin or Zoladex.
- 50. A composition according to claim 48, wherein said composition is in the form of a depot formulation.